Evidence map›Paper›PMID 33733078›Full record

ArticleJHEP reports : innovation in hepatology2021

European 'NAFLD Preparedness Index' - Is Europe ready to meet the challenge of fatty liver disease?

Jeffrey V Lazarus, Adam Palayew, Patrizia Carrieri, Mattias Ekstedt, Giulio Marchesini, Katja Novak, Vlad Ratziu, Manuel Romero-Gómez, Frank Tacke, Shira Zelber-Sagi and 2 more

Abstract read
In one paragraph

Article in JHEP reports : innovation in hepatology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed, 2 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

28 citing papers in PubMed, 2 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Article
  4. Review
  5. Review
  6. Review
  7. Review
  8. Article
  9. Review
  10. Article
  11. Article
  12. Current strategies for nonalcoholic fatty liver disease treatment (Review).International journal of molecular medicine · 2024
    Review
  13. Article
  14. Article
  15. Article
  16. Banting memorial lecture 2022: 'Type 2 diabetes and nonalcoholic fatty liver disease: Partners in crime'.Diabetic medicine : a journal of the British Diabetic Association · 2022
    Review
  17. Article
  18. Article
  19. Knowledge of liver fibrosis stage among adults with NAFLD/NASH improves adherence to lifestyle changes.Liver international : official journal of the International Association for the Study of the Liver · 2022
    Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Jeffrey V LazarusBarcelona Institute for Global Health (ISGlobal), Hospital Clínic, University of Barcelona, Barcelona, Spain.
Adam PalayewMcGill University Department of Epidemiology, Biostatistics, and Occupational Health, Montreal, Canada.
Patrizia CarrieriAix Marseille Université, INSERM, IRD, SESSTIM, Sciences Economiques et Sociales de la Santé et Traitement de l'Information Médicale, Marseille, France.
Mattias EkstedtDivision of Diagnostics and Specialist Medicine, Department of Health, Medicine, and Caring Sciences, Linköping University, Linköping, Sweden.
Giulio MarchesiniIRCCS-AOU Bologna, and Department of Medical and Surgical Sciences, 'Alma Mater' University, Bologna, Italy.
Katja NovakUniversity Medical Center Ljubljana, Department of Gastroenterology, Ljubljana, Slovenia.
Vlad RatziuPitie-Salpetriere Hospital, Department of Hepatology University Paris, Paris, France.
Manuel Romero-GómezUCM Digestive Diseases, CIBEREHD, and IBIS, Virgen del Rocío University Hospital, University of Seville, Seville, Spain.
Frank TackeCharité University Medicine Berlin, Department of Hepatology and Gastroenterology, Berlin, Germany.
Shira Zelber-SagiUniversity of Haifa, Faculty of Social Welfare and Health Sciences, School of Public Health, Mount Carmel, Haifa, Israel.
Helena Cortez-PintoClínica Universitária de Gastrenterologia, Laboratório de Nutrição, Faculdade de Medicina, Universidade de Lisboa, Lisbon, Portugal.
Quentin M AnsteeTranslational & Clinical Research Institute, Faculty of Medical Sciences, Newcastle University, Newcastle upon Tyne, UK.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

BACKGROUND &

aimsNon-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent emerging condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to ensure that health systems can deliver effective care. We present a NAFLD Preparedness Index for Europe.

methodsIn June 2019, data were extracted by expert groups from 29 countries to complete a 41-item questionnaire about NAFLD. Questions were classified into 4 categories: policies/civil society (9 questions), guidelines (16 questions), epidemiology (4 questions), and care management (12 questions). Based on the responses, national preparedness for each indicator was classified into low, middle, or high-levels. We then applied a multiple correspondence analysis to obtain a standardised preparedness score for each country ranging from 0 to 100.

resultsThe analysis estimated a summary factor that explained 71.3% of the variation in the dataset. No countries were found to have yet attained a high-level of preparedness. Currently, the UK (75.5) scored best, although falling within the mid-level preparedness band, followed by Spain (56.2), and Denmark (43.4), whereas Luxembourg and Ireland were the lowest scoring countries with a score of 4.9. Only Spain scored highly in the epidemiology indicator category, whereas the UK was the only country that scored highly for care management.

conclusionsThe NAFLD Preparedness Index indicates substantial variation between countries' readiness to address NAFLD. Notably, even those countries that score relatively highly exhibit deficiencies in key domains, suggesting that structural changes are needed to optimise NAFLD management and ensure effective public health approaches are in place. LAY SUMMARY: Non-alcoholic fatty liver disease (NAFLD), which is closely associated with obesity, metabolic syndrome, and diabetes, is a highly prevalent condition that can be optimally managed through a multidisciplinary patient-centred approach. National preparedness to address NAFLD is essential to allow for effective public health measures aimed at preventing disease while also ensuring that health systems can deliver effective care to affected populations. This study defined preparedness as having adequate policies and civil society engagement, guidelines, epidemiology, and care management. NAFLD preparedness was found to be deficient in all 29 countries studied, with great variation among the countries and the 4 categories studied.

Indexed as

EASD, European Association for the Study of DiabetesEASL, European Association for the Study of the LiverEASO, European Association for the Study of ObesityEEA, European Economic AreaESPEN, European Society of Clinical Nutrition and MetabolismEU, European UnionEuropeHealth policyLiver healthMCA, multiple correspondence analysisMetabolic-associated fatty liver diseaseMultiple joint correspondence analysisNAFLD, non-alcoholic fatty liver diseaseNASH, non-alcoholic steatohepatitisNon-alcoholic fatty liver diseaseNon-alcoholic steatohepatitisPolicy preparednessT2DM, type 2 diabetes mellitusWHO, World Health Organization

Identifiers

PMID33733078
PMCPMC7937562

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.